a Communicable Disease Division, Surveillance and Epidemiology Branch , Centre for Health Protection, Department of Health , Kowloon , Hong Kong SAR Government.
Hum Vaccin Immunother. 2019;15(1):97-101. doi: 10.1080/21645515.2018.1514222. Epub 2018 Oct 23.
The 2017/18 winter influenza season in Hong Kong started in early January 2018, predominated by influenza B/Yamagata. We collaborated with private medical practitioners of our sentinel surveillance system to collect respiratory specimens and clinical information from patients with influenza-like illness for estimation of the influenza vaccine effectiveness (VE) using the test-negative case-control design. We found that the overall VE was 59.1% (95%CI 41.1 to 71.8%) against all influenza and 53.5% (95%CI 35.4 to 74.6%) against influenza B. Seasonal influenza vaccine provided moderate to good protection against laboratory-confirmed influenza infection at primary care level in Hong Kong in the 2017/18 winter influenza season.
2017/18 年冬季流感季于 2018 年 1 月初在香港开始，主要由乙型流感/Yamagata 主导。我们与哨点监测系统的私人执业医生合作，从流感样病例患者中收集呼吸道标本和临床信息，使用病例对照试验阴性设计来估计流感疫苗的效果（VE）。我们发现，总体 VE 为 59.1%（95%CI 41.1 至 71.8%），对所有流感和 53.5%（95%CI 35.4 至 74.6%）对乙型流感有效。在 2017/18 年冬季流感季，季节性流感疫苗在香港基层医疗水平对实验室确诊的流感感染提供了中等至良好的保护。
